WEBULL
News
NRSN
0.8182
-1.42%
-0.0118
Weekly Report: what happened at NRSN last week (1208-1212)?
Weekly Report · 3d ago
Noble Financial Remains a Buy on Neurosense Therapeutics Ltd. (NRSN)
TipRanks · 12/09 14:35
NeuroSense Therapeutics Locks Database For Phase 2 RoAD Study Of PrimeC In Alzheimer's; Topline Results Expected Q1 2026
Benzinga · 12/08 19:11
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 12/08 17:05
NeuroSense Completes Data Collection for Alzheimer’s Trial
TipRanks · 12/08 13:27
NeuroSense Therapeutics Locks Database for Phase 2 Alzheimer's Trial with Topline Results Expected in 2026
Reuters · 12/08 13:01
Weekly Report: what happened at NRSN last week (1201-1205)?
Weekly Report · 12/08 09:57
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug
TipRanks · 12/04 13:58
BRIEF-Neurosense Therapeutics Ltd - Resuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis
Reuters · 12/04 13:44
NeuroSense Therapeutics Resumes Regulatory Push in Canada for ALS Drug PrimeC After Productive Talks
Benzinga · 12/04 12:32
Weekly Report: what happened at NRSN last week (1124-1128)?
Weekly Report · 12/01 09:54
Alliance Global Partners Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)
TipRanks · 11/28 07:05
BUZZ-U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
Reuters · 11/24 18:52
NeuroSense Gains FDA Approval for Phase 3 ALS Trial
TipRanks · 11/24 16:37
NeuroSense Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 11/24 15:56
NeuroSense Therapeutics Price Target Maintained With a $14.00/Share by D. Boral Capital
Dow Jones · 11/24 15:56
BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Reuters · 11/24 15:52
D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target
Benzinga · 11/24 15:46
NeuroSense reports FDA clearance to initiate Phase 3 trial for PrimeC in ALS
TipRanks · 11/24 15:05
FDA Completes Review Of IND Amendment Application And Authorizes NeuroSense To Initiate Pivotal Phase 3 Clinical Trial For Evaluation Of PrimeC, For ALS Treatment
Benzinga · 11/24 14:59
More
Webull provides a variety of real-time NRSN stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSN
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease